Febuxostat (Uloric) for chronic treatment of gout

Medical Letter on Drugs and Therapeutics

Volumn 51, Issue 1312, 2009, Pages 37-38

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; FEBUXOSTAT; MERCAPTOPURINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; THEOPHYLLINE; ULORIC; UNCLASSIFIED DRUG; URATE; URIC ACID; ANTIGOUT AGENT; THIAZOLE DERIVATIVE;

AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; BONE MARROW DEPRESSION; CHRONIC DRUG ADMINISTRATION; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GOUT; HEART INFARCTION; HUMAN; HYPERSENSITIVITY REACTION; HYPERURICEMIA; KIDNEY FAILURE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OPTIMAL DRUG DOSE; RASH; SHORT SURVEY; SIDE EFFECT; STROKE; SURVIVAL; TIME TO MAXIMUM PLASMA CONCENTRATION; URIC ACID BLOOD LEVEL; VASCULITIS; CHRONIC DISEASE; CLINICAL TRIAL; DRUG INTERACTION; REVIEW;

CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; GOUT; GOUT SUPPRESSANTS; HUMANS; THIAZOLES;

EID: 66649090459     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (6)

1. MP Keith et al. Updates in the management of gout. Am J Med 2007; 120:221.
2. MA Becker et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353:2450.
3. HR Schumacher Jr. et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008; 59:1540.
4. M Becker et al. A phase 3 randomized, controlled, multicenter, double-blind trial (RCT) comparing efficacy and safety of daily febuxostat (FEB) and allopurinol (ALLO) in subjects with gout. Presented at 2008 annual scientific meeting of the American College of Rheumatology, October 24-29, 2008, San Francisco, CA. Late breaking abstract L11. Available at www.rheumatology.org/annual/index.asp. Accessed May 5, 2009.
5. MA Becker et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009 Mar 13 [Epub ahead of print].
6. HR Schumacher Jr. et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 2009; 48:188.